Karyopharm Therapeutics Inc Share Price Today: Live Updates & Key Insights
Karyopharm Therapeutics Inc share price today is $7.6857, up -1.29%. The stock opened at $7.79 against the previous close of $7.73, with an intraday high of $9.01 and low of $7.435.
Karyopharm Therapeutics Inc Share Price Chart
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc Share Price Performance
Karyopharm Therapeutics Inc Institutional Holdings
Karyopharm Therapeutics Inc Market Status
Karyopharm Therapeutics Inc Fundamentals
Market Cap 139.96 M
PB Ratio 12.0484
PE Ratio 0.0
Enterprise Value 309.83 M
Total Assets 108.42 M
Volume 1496158
Karyopharm Therapeutics Inc Company Financials
About Karyopharm Therapeutics Inc & investment objective
Company Information Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Organisation Biotechnology
Employees 228
Industry Biotechnology
CEO Mr. Richard A. Paulson M.B.A.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Karyopharm Therapeutics Inc FAQs
What is the share price of Karyopharm Therapeutics Inc today?
The current share price of Karyopharm Therapeutics Inc is $7.6857.
Can I buy Karyopharm Therapeutics Inc shares in India?
Yes, Indian investors can buy Karyopharm Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.
How to buy Karyopharm Therapeutics Inc shares in India?
You can easily invest in Karyopharm Therapeutics Inc shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Karyopharm Therapeutics Inc shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Karyopharm Therapeutics Inc.
Can I buy fractional shares of Karyopharm Therapeutics Inc?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Karyopharm Therapeutics Inc?
Karyopharm Therapeutics Inc has a market cap of $139.96 M.
In which sector does Karyopharm Therapeutics Inc belong?
Karyopharm Therapeutics Inc operates in the Biotechnology sector.
What documents are required to invest in Karyopharm Therapeutics Inc stocks?
To invest, you typically need:
What is the PE and PB ratio of Karyopharm Therapeutics Inc?
The PE ratio of Karyopharm Therapeutics Inc is N/A and the PB ratio is 12.05.